# EDGAR Filing Document

**Accession Number:** 0002011156
**File Stem:** 0001213900-25-064242
**Filing Date:** 2025-7
**Character Count:** 12658
**Document Hash:** b200a72420323fc4abc1328160646dfb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-064242.hdr.sgml**: 20250715

**ACCESSION NUMBER**: 0001213900-25-064242

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250715

**DATE AS OF CHANGE**: 20250715

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LakeShore Biopharma Co., Ltd.
- **CENTRAL INDEX KEY:** 0001946399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94412
- **FILM NUMBER:** 251124665

**BUSINESS ADDRESS:**
- **STREET 1:** BUILDING NO. 2, 38 YONGDA ROAD
- **STREET 2:** DAXING BIOMEDICAL INDUSTRY PARK
- **CITY:** DAXING DISTRICT, BEIJING
- **STATE:** F4
- **ZIP:** 102629
- **BUSINESS PHONE:** 17327133678

**MAIL ADDRESS:**
- **STREET 1:** BUILDING NO. 2, 38 YONGDA ROAD
- **STREET 2:** DAXING BIOMEDICAL INDUSTRY PARK
- **CITY:** DAXING DISTRICT, BEIJING
- **STATE:** F4
- **ZIP:** 102629

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** YS Biopharma Co., Ltd.
- **DATE OF NAME CHANGE:** 20230310

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** YishengBio Co., Ltd
- **DATE OF NAME CHANGE:** 20220912
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Wong Fung Ching
- **CENTRAL INDEX KEY:** 0002011156

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 37370 CEDAR BLVD, STE
- **CITY:** NEWARK
- **STATE:** CA
- **ZIP:** 94560

## Exhibit 99.1

**Exhibit 99.1**

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the ordinary shares, par value $0.0002 per share, of LakeShore Biopharma Co., Ltd, a Cayman Islands exempted company, and that this Agreement may be included as an exhibit to such joint filing. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned hereby execute this Agreement as of July 15, 2025.

---

| | |
|:---|:---|
| **Apex Prospect Limited** | **Apex Prospect Limited** |
| By: | /s/ Fung Ching Wong |
| Name: | Fung Ching Wong |
| Title: | Director |
| **Fung Ching Wong** | **Fung Ching Wong** |
| /s/ Fung Ching Wong | /s/ Fung Ching Wong |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**LakeShore Biopharma Co., Ltd.**

*(Name of Issuer)*

**Ordinary Shares, par value $0.0002 per share**

*(Title of Class of Securities)*

**G9845F208**

*(CUSIP Number)*

**Fung Ching Wong**<br>Floor 4, Willow House<br>Cricket Square, P O Box 2804<br>Grand Cayman E9 KY1-1112<br>1 5603646852

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**07/11/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **G9845F208** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Fung Ching Wong** | Name of reporting person<br>**Fung Ching Wong** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CHINA** | Citizenship or place of organization<br>**CHINA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**9836010.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**9836010.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**9836010.00** | Aggregate amount beneficially owned by each reporting person<br>**9836010.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**23.9%** | Percent of class represented by amount in Row (11)<br>**23.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Notes in relation to Items 8, 10 and 11: This reflects the 10-for-1 share consolidation effective October 1, 2024 (the "Share Consolidation"), whereby the 98,360,094 ordinary shares, par value $0.00002 per share of the Issuer (as defined below) reported in the original Schedule 13D were consolidated into 9,836,010 Ordinary Shares (as defined below). Ms. Fung Ching Wong ("Ms. Wong") currently exercises voting and dispositive control over the Ordinary Shares registered in the names of Apex Prospect Limited ("Apex"). Apex and Ms. Wong may each be deemed to have shared voting and dispositive power over all of the shares.

Notes in relation to Item 13: This percentage is calculated based on 41,212,693 Ordinary Shares issued and outstanding as of July 11, 2025, which is provided by the Issuer to the Reporting Persons (as defined below). The increase in the total number of issued shares is a result of a private placement financing announced by the Issuer on July 8, 2025.

| **CUSIP No.** | **G9845F208** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Apex Prospect Limited** | Name of reporting person<br>**Apex Prospect Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**9836010.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**9836010.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**9836010.00** | Aggregate amount beneficially owned by each reporting person<br>**9836010.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**23.9%** | Percent of class represented by amount in Row (11)<br>**23.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** Notes in relation to Items 8, 10 and 11: This reflects the 10-for-1 Share Consolidation effective October 1, 2024, whereby the 98,360,094 ordinary shares, par value $0.00002 per share of the Issuer reported in the original Schedule 13D were consolidated into 9,836,010 Ordinary Shares. Ms. Wong currently exercises voting and dispositive control over the Ordinary Shares registered in the names of Apex. Apex and Ms. Wong may each be deemed to have shared voting and dispositive power over all of the shares.

Notes in relation to Item 13: This percentage is calculated based on 41,212,693 Ordinary Shares issued and outstanding as of July 11, 2025, which is provided by the Issuer to the Reporting Persons (as defined below). The increase in the total number of issued shares is a result of a private placement financing announced by the Issuer on July 8, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, par value $0.0002 per share

**(b) Name of Issuer:**
LakeShore Biopharma Co., Ltd.

**(c) Address of Issuer's Principal Executive Offices:**
Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, F4, 102629

This Amendment No. 1 ("Amendment No. 1") amends and supplements the Schedule 13D originally filed with the Securities and Exchange Commission on February 14, 2024 (the "Original Schedule 13D"), by Fung Ching Wong and Apex Prospect Limited (the "Reporting Persons"), with respect to the ordinary shares of LakeShore Biopharma Co., Ltd (formerly known as YS Biopharma Co., Ltd.) (the "Issuer").

Capitalized terms used herein without definition shall have the meanings set forth in the Original Schedule 13D. Except as specifically amended and supplemented by this Amendment No. 1, the Original Schedule 13D remains in full force and effect.

**Item 4. Purpose of Transaction**

Item 4 of the Original Schedule 13D is hereby amended to add the following information:

This Amendment No. 1 is being filed to report a material decrease in the Reporting Persons' percentage of beneficial ownership of the Issuer's Ordinary Shares. This decrease resulted solely from an increase in the total number of the Issuer's issued Ordinary Shares following a private placement transaction announced by the Issuer on July 8, 2025. The Reporting Persons have not sold or otherwise disposed of any of the Ordinary Shares they beneficially own.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The responses of the Reporting Persons to Rows (7) through (13) of the cover pages of this Amendment No. 1 are incorporated herein by reference. As of July 11, 2025, the Reporting Persons may be deemed to be the beneficial owners of an aggregate of 9,836,010 Ordinary Shares, which represents approximately 23.9% of the Issuer's issued and outstanding Ordinary Shares.

The number of Ordinary Shares reported as beneficially owned reflects the 10-for-1 Share Consolidation undertaken by the Issuer, effective October 1, 2024. Pursuant to the Share Consolidation, the 98,360,094 Ordinary Shares previously reported as beneficially owned by the Reporting Persons were consolidated into 9,836,010 Ordinary Shares.

The percentage of beneficial ownership is based on 41,212,693 Ordinary Shares issued and outstanding as of July 11, 2025, which figure is provided by the Issuer to the Reporting Persons.

**(b)**
Each of the Reporting Persons has shared power to vote or to direct the vote of, and shared power to dispose or to direct the disposition of, the 9,836,010 Ordinary Shares reported herein.

**(c)**
None of the Reporting Persons has effected any transaction during the past 60 days in any Ordinary Shares.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Fung Ching Wong

**Signature:** /s/ Fung Ching Wong

**Name/Title:** Fung Ching Wong

**Date:** 07/15/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Apex Prospect Limited

**Signature:** /s/ Fung Ching Wong

**Name/Title:** Fung Ching Wong, Director

**Date:** 07/15/2025